Uppsala, Sweden – October 27, 2017 – Orexo AB (publ.) (the “Company”) announces today that the Company will issue a notice of conditional early total redemption (the “Notice”) of its outstanding SEK 342,000,000 (excluding the amount held by the Company) senior unsecured callable floating rate bonds due 2018 with ISIN SE0005932159 (the “Bonds”) in accordance with the terms and conditions of the Bonds.
The redemption of the Bonds is scheduled to occur on 22 November 2017 (the “Early Redemption Date”). The record date for the early redemption will be 15 November 2017 (the “Record Date”) and the Bonds will be redeemed at 101.00 per cent. of the nominal amount (i.e. SEK 1,010,000 per Bond, the nominal amount being SEK 1,000,000) together with accrued but unpaid interest from, but excluding, the interest payment date on 9 November 2017, up to, and including, the Early Redemption Date. In conjunction with the redemption, the Bonds will be delisted from the corporate bond list of Nasdaq Stockholm.
The Notice will be irrevocable but is subject to the completion of issuance of new bonds at a minimum aggregate amount of SEK 300,000,000 prior to the Record Date (the “Condition”). The Company has appointed Pareto Securities as sole bookrunner in relation to such process. The fulfilment of the Condition will be confirmed to the bondholders through a press release. Should the Condition not be fulfilled by the Record Date or has not otherwise been waived by the Company (at the Company’s sole discretion), the Bonds will not be redeemed in accordance with the Notice which will, in such case, be confirmed to the bondholders through a press release.
This communication is, for the avoidance of doubt, not an offer to purchase or sell financial instruments.
For further information, please contact:
|Orexo AB (publ.)|
|Nikolaj Sørensen, President and CEO||Henrik Juuel, EVP and CFO|
|Tel: +46 (0)18 780 88 00||Tel: +46 (0)18 780 88 00|
|E-mail: firstname.lastname@example.org||E-mail: email@example.com|
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.
This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation, through the agency of the contact persons set out above. The information was submitted for publication at 8.50 am CET on 27 October 2017.